Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.45 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$55.46B
Enterprise ValueHK$37.47B
Total Cash (Recent Filing)HK$2.97B
Total Debt (Recent Filing)HK$7.08B
Price to Earnings (P/E)30.3
Beta1.88
Next Earnings
Aug 31, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.65Price Target Upside22.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$18.64B
Bulls Say, Bears Say
Bulls Say
Integrated R&D-to-manufacturing ModelPharmaron’s end-to-end service model (discovery through manufacturing) creates durable client stickiness and cross-sell opportunities. That breadth diversifies revenue across project types, raises lifetime client value, and positions the company to capture structural outsourcing demand from biopharma over multiple development stages.
Sustained Profitability MarginsMid-teens operating margins and double-digit net margins provide a structural earnings cushion versus lower-margin peers. Persistent profitability supports reinvestment in capabilities, funds capacity expansion, and allows the firm to absorb cyclical slowdowns without immediate restructuring, strengthening long-term competitiveness.
Low Leverage And Stronger Balance SheetA low debt-to-equity ratio and growing equity provide financial flexibility to invest in capacity, absorb working-capital swings, and pursue M&A or strategic partnerships. This reduces refinancing risk and supports sustained service delivery during sector cycles, a structural advantage for a capital-intensive CDMO/CRDMO business.
Bears Say
Weak And Volatile Cash ConversionSubpar cash conversion and sharply declining free cash flow indicate recurring working-capital strain or heavy reinvestment needs. Over the medium term, weak FCF limits self-funded growth, increases dependence on external funding for capex or capacity, and raises sensitivity to project timing and client payment patterns.
Slowing Revenue GrowthA material deceleration in top-line growth reduces utilization-driven leverage in a services business where fixed capacity matters. Persistently slower revenue growth can pressure margins, limit operating leverage, and make it harder to amortize R&D and manufacturing investments, weakening medium-term return prospects.
Margin Compression From Prior LevelsSustained margin compression suggests structural pricing pressure, rising input costs, or an adverse mix toward lower-margin work. If persistent, this erodes cash flow generation and ROIC, constraining capacity investments and reducing the firm’s ability to differentiate on service or price versus competitors over the next several quarters.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$55.46B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 58 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.212 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.028.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.23 which represents an annual dividend yield of 1.04%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.29.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$29.65 (22.83% Upside)
HK$29.65 (22.83% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
11.22%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
3759 Stock 12 Month Forecast
Average Price Target
HK$29.65
▲(22.83% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---